AstraZeneca's earnings top estimates but shares fall on core operating profit drop
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AstraZeneca (AZN) Tops Q4 EPS by 71c; initiates guidance
February 8, 2024 2:55 AM ESTAstraZeneca (NASDAQ: AZN) reported Q4 EPS of $1.45, $0.71 better than the analyst estimate of $0.74. Revenue for the quarter came in at $12.02 billion versus the consensus estimate of $12 billion.
GUIDANCE:
The Company issues its Total Revenue and Core EPS guidance for... More
